Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Christopher Richard Anzalone Sells 51,425 Shares of Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Christopher Richard Anzalone sold 51,425 shares of Arrowhead Pharmaceuticals stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $15.07, for a total transaction of $774,974.75. Following the sale, the chief executive officer now owns 4,062,377 shares of the company’s stock, valued at $61,220,021.39. The trade was a 1.25 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Christopher Richard Anzalone also recently made the following trade(s):

• On Tuesday, March 4th, Christopher Richard Anzalone sold 133,333 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $17.02, for a total transaction of $2,269,327.66.
• On Thursday, January 2nd, Christopher Richard Anzalone sold 11,520 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $19.05, for a total transaction of $219,456.00.
• On Monday, December 23rd, Christopher Richard Anzalone sold 12,563 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $19.59, for a total transaction of $246,109.17.
• On Wednesday, December 18th, Christopher Richard Anzalone sold 26,712 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $21.24, for a total transaction of $567,362.88.

Arrowhead Pharmaceuticals Trading Up 1.6 %

Shares of ARWR stock opened at $15.60 on Tuesday. The company has a 50-day moving average of $18.93 and a two-hundred day moving average of $20.11. The company has a debt-to-equity ratio of 7.27, a current ratio of 6.09 and a quick ratio of 6.09. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $14.23 and a 1-year high of $30.41. The firm has a market cap of $2.14 billion, a PE ratio of -3.02 and a beta of 0.92.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.97). On average, analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Institutional Trading of Arrowhead Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the company. World Investment Advisors LLC raised its holdings in Arrowhead Pharmaceuticals by 3.8% during the third quarter. World Investment Advisors LLC now owns 19,132 shares of the biotechnology company’s stock worth $371,000 after purchasing an additional 700 shares in the last quarter. Xponance Inc. raised its holdings in Arrowhead Pharmaceuticals by 4.5% during the fourth quarter. Xponance Inc. now owns 17,400 shares of the biotechnology company’s stock worth $327,000 after purchasing an additional 744 shares in the last quarter. Summit Investment Advisors Inc. raised its holdings in Arrowhead Pharmaceuticals by 2.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 37,994 shares of the biotechnology company’s stock worth $714,000 after purchasing an additional 803 shares in the last quarter. Wellington Management Group LLP raised its holdings in Arrowhead Pharmaceuticals by 1.5% during the third quarter. Wellington Management Group LLP now owns 61,904 shares of the biotechnology company’s stock worth $1,199,000 after purchasing an additional 886 shares in the last quarter. Finally, ADAR1 Capital Management LLC raised its holdings in Arrowhead Pharmaceuticals by 10.2% during the fourth quarter. ADAR1 Capital Management LLC now owns 12,900 shares of the biotechnology company’s stock worth $243,000 after purchasing an additional 1,195 shares in the last quarter. Institutional investors and hedge funds own 62.61% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. StockNews.com raised shares of Arrowhead Pharmaceuticals to a “sell” rating in a research report on Friday, December 20th. Royal Bank of Canada reissued an “outperform” rating and set a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. B. Riley reissued a “buy” rating and set a $38.00 target price (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. Sanford C. Bernstein dropped their target price on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating on the stock in a research report on Friday, November 29th. Finally, Citigroup dropped their target price on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 27th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, Arrowhead Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $41.44.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.